IRIS Accounts Production v26.1.0.640 15996335 director 3.10.24 31.10.25 31.10.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 15996335 2024-10-02 15996335 2025-10-31 15996335 2024-10-03 2025-10-31 15996335 2024-10-02 15996335 ns15:EnglandWales 2024-10-03 2025-10-31 15996335 ns14:PoundSterling 2024-10-03 2025-10-31 15996335 ns10:Director1 2024-10-03 2025-10-31 15996335 ns10:PrivateLimitedCompanyLtd 2024-10-03 2025-10-31 15996335 ns10:SmallEntities 2024-10-03 2025-10-31 15996335 ns10:AuditExempt-NoAccountantsReport 2024-10-03 2025-10-31 15996335 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-03 2025-10-31 15996335 ns10:SmallCompaniesRegimeForAccounts 2024-10-03 2025-10-31 15996335 ns10:FullAccounts 2024-10-03 2025-10-31 15996335 ns5:CurrentFinancialInstruments 2025-10-31 15996335 ns5:ShareCapital 2025-10-31 15996335 ns5:RetainedEarningsAccumulatedLosses 2025-10-31 15996335 ns5:PlantMachinery 2024-10-03 2025-10-31 15996335 ns5:PlantMachinery 2025-10-31 15996335 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-10-31

REGISTERED NUMBER: 15996335 (England and Wales)

Unaudited Financial Statements

for the Period 3 October 2024 to 31 October 2025

for

Carthy Pharma Quality Limited

Carthy Pharma Quality Limited (Registered number: 15996335)

Contents of the Financial Statements

for the Period 3 October 2024 to 31 October 2025

Page |

Balance Sheet | 1 |

Notes to the Financial Statements | 2 |

Carthy Pharma Quality Limited (Registered number: 15996335)

Balance Sheet

31 October 2025

| Notes | £ |

| FIXED ASSETS

| Tangible assets | 4 | 1,609 |  |

| CURRENT ASSETS

| Debtors | 5 | 18,144 |  |

| Cash at bank | 30,790 |  |

48,934 |  |

| CREDITORS

| Amounts falling due within one year | 6 | (30,454 | ) |

| NET CURRENT ASSETS | 18,480 |  |

| TOTAL ASSETS LESS CURRENT LIABILITIES | 20,089 |  |

| CAPITAL AND RESERVES

| Called up share capital | 100 |  |

| Retained earnings | 19,989 |  |

20,089 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 October 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 October 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 March 2026 and were signed by:

T Carthy - Director

Carthy Pharma Quality Limited (Registered number: 15996335)

Notes to the Financial Statements

for the Period 3 October 2024 to 31 October 2025

1. | STATUTORY INFORMATION

| Carthy Pharma Quality Limited is a private company, limited by shares, registered in England, registration number 15996335. The registered office is Crown House, 27 Old Gloucester Street, London, United Kingdom, WC1N 3AX.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover represents net invoiced sales of goods and services in respect of IT Consultancy, using the flat rate scheme for value added tax. Sales are recognised at the point at which the goods are delivered or the service is complete.

| Tangible fixed assets and depreciation

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Computer equipment - 25% on cost

| Tangible fixed assets are stated at cost less depreciation. Cost represent purchase price together with any incidental costs of acquisition.

| The directors have considered the residual value of all tangible fixed assets to be immaterial and therefore all tangible fixed assets are depreciated to nil value.

| Taxation

| Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Carthy Pharma Quality Limited (Registered number: 15996335)

Notes to the Financial Statements - continued

for the Period 3 October 2024 to 31 October 2025

2. | ACCOUNTING POLICIES - continued

| Provisions

| Provisions are recognised when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of resources will be required to settle the obligation, and the amount has been reliably estimated. Provisions are not recognised for future operating losses. Provisions are discounted where the time value of money is material.

| Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the period was 1 .

4. | TANGIBLE FIXED ASSETS

| Plant and

| machinery

| etc

£ |

| COST

| Additions | 2,145 |  |

| At 31 October 2025 | 2,145 |  |

| DEPRECIATION

| Charge for period | 536 |  |

| At 31 October 2025 | 536 |  |

| NET BOOK VALUE

| At 31 October 2025 | 1,609 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

£ |

| Trade debtors | 18,144 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

£ |

| Taxation and social security | 28,443 |  |

| Other creditors | 2,011 |  |

30,454 |  |